nach oben

Metabolic Brain Disease

Erschienen in:

01.04.2016 | Review Article

Potential roles of fibroblast growth factor 21 in the brain

verfasst von: Piangkwan Sa-nguanmoo, Nipon Chattipakorn, Siriporn C. Chattipakorn

Erschienen in: Metabolic Brain Disease | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Fibroblast growth factor 21 (FGF21) is an endocrine hormone, playing an important role in the regulation of metabolism. FGF21 is primarily expressed by several tissues, including liver, pancreas, thymus, heart, muscle, adipose tissue, and brain. In addition to the effects of FGF21 in lowering glucose and lipid levels, increasing insulin sensitivity and regulating energy homeostasis in rodents and non-human primate models of diabetes and obesity, previous reports have demonstrated that FGF21 also plays an important role in the brain involving it in potential effects in metabolic regulation, neuroprotection and cognition. In this review, the current available evidence from both in vitro and in vivo investigations regarding the roles of FGF21 and its function in the brain are comprehensively summarized. In addition, the mechanistic insights regarding the roles of FGF21 in the brain and its potential neuroprotective benefits are also presented and discussed.

Adams AC, Cheng CC, Coskun T, Kharitonenkov A (2012) FGF21 requires betaklotho to act in vivo. PLoS One 7, e49977. doi:10.1371/journal.pone.0049977 CrossRefPubMedPubMedCentral

An SY et al (2012) Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract 96:196–203. doi:10.1016/j.diabres.2012.01.004 CrossRefPubMed

Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5:426–437. doi:10.1016/j.cmet.2007.05.002 CrossRefPubMed

Biessels GJ, Kappelle LJ, Utrecht Diabetic Encephalopathy Study G (2005) Increased risk of Alzheimer’s disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 33:1041–1044. doi:10.1042/BST20051041 CrossRefPubMed

Bookout AL et al (2013) FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med 19:1147–1152. doi:10.1038/nm.3249 CrossRefPubMedPubMedCentral

Brahma MK et al (2014) Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis. J Lipid Res 55:2229–2241. doi:10.1194/jlr.M044784 CrossRefPubMedPubMedCentral

Cyphert HA, Alonge KM, Ippagunta SM, Hillgartner FB (2014) Glucagon stimulates hepatic FGF21 secretion through a PKA- and EPAC-dependent posttranscriptional mechanism. PLoS One 9, e94996. doi:10.1371/journal.pone.0094996 CrossRefPubMedPubMedCentral

De Sousa-Coelho AL, Marrero PF, Haro D (2012) Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation. Biochem J 443:165–171. doi:10.1042/BJ20111748 CrossRefPubMed

Ding X, Boney-Montoya J, Owen BM, Bookout AL, Coate KC, Mangelsdorf DJ, Kliewer SA (2012) betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab 16:387–393. doi:10.1016/j.cmet.2012.08.002 CrossRefPubMedPubMedCentral

Douris N et al (2015) Central fibroblast growth factor 21 browns white fat via sympathetic action in male mice. Endocrinology 156:2470–2481. doi:10.1210/en.2014-2001 CrossRefPubMed

Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, Kliewer SA (2012) Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 148:556–567. doi:10.1016/j.cell.2011.11.062 CrossRefPubMedPubMedCentral

Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, Maratos-Flier E (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59:2781–2789. doi:10.2337/db10-0193 CrossRefPubMedPubMedCentral

Fon Tacer K et al (2010) Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 24:2050–2064. doi:10.1210/me.2010-0142 CrossRefPubMedPubMedCentral

Galman C et al (2008) The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 8:169–174. doi:10.1016/j.cmet.2008.06.014 CrossRefPubMed

Ge H et al (2012) Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism. PLoS One 7, e33603. doi:10.1371/journal.pone.0033603 CrossRefPubMedPubMedCentral

Greenwood CE, Winocur G (2005) High-fat diets, insulin resistance and declining cognitive function. Neurobiol Aging 26(Suppl 1):42–45. doi:10.1016/j.neurobiolaging.2005.08.017 CrossRefPubMed

Hale C et al (2012) Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology 153:69–80. doi:10.1210/en.2010-1262 CrossRefPubMed

Hindricks J et al (2014) Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. Clin Endocrinol 80:918–924. doi:10.1111/cen.12380 CrossRef

Hondares E, Iglesias R, Giralt A, Gonzalez FJ, Giralt M, Mampel T, Villarroya F (2011) Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem 286:12983–12990. doi:10.1074/jbc.M110.215889 CrossRefPubMedPubMedCentral

Houten SM, Auwerx J (2004) PGC-1alpha: turbocharging mitochondria. Cell 119:5–7. doi:10.1016/j.cell.2004.09.016 CrossRefPubMed

Hsuchou H, Pan W, Kastin AJ (2007) The fasting polypeptide FGF21 can enter brain from blood. Peptides 28:2382–2386. doi:10.1016/j.peptides.2007.10.007 CrossRefPubMedPubMedCentral

Huang X et al (2013) The cell adhesion molecule L1 regulates the expression of FGF21 and enhances neurite outgrowth. Brain Res 1530:13–21. doi:10.1016/j.brainres.2013.07.043 CrossRefPubMed

Inagaki T et al (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2:217–225. doi:10.1016/j.cmet.2005.09.001 CrossRefPubMed

Inagaki T et al (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5:415–425. doi:10.1016/j.cmet.2007.05.003 CrossRefPubMed

Ishida N (2009) Role of PPARalpha in the control of torpor through FGF21-NPY pathway: from circadian clock to seasonal change in mammals. PPAR Res 2009:412949. doi:10.1155/2009/412949 CrossRefPubMedPubMedCentral

Itoh N, Ornitz DM (2011) Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 149:121–130. doi:10.1093/jb/mvq121 CrossRefPubMedPubMedCentral

Kharitonenkov A (2009) FGFs and metabolism. Curr Opin Pharmacol 9:805–810. doi:10.1016/j.coph.2009.07.001 CrossRefPubMed

Kharitonenkov A, Shanafelt AB (2009) FGF21: a novel prospect for the treatment of metabolic diseases. Curr Opin Investig Drugs 10:359–364PubMed

Kharitonenkov A et al (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115:1627–1635. doi:10.1172/JCI23606 CrossRefPubMedPubMedCentral

Kim KH, Kim SH, Min YK, Yang HM, Lee JB, Lee MS (2013) Acute exercise induces FGF21 expression in mice and in healthy humans. PLoS One 8, e63517. doi:10.1371/journal.pone.0063517 CrossRefPubMedPubMedCentral

Liang Q et al (2014) FGF21 Maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes 63:4064–4075. doi:10.2337/db14-0541 CrossRefPubMed

Lin J, Handschin C, Spiegelman BM (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1:361–370. doi:10.1016/j.cmet.2005.05.004 CrossRefPubMed

Lundasen T, Hunt MC, Nilsson LM, Sanyal S, Angelin B, Alexson SE, Rudling M (2007) PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 360:437–440. doi:10.1016/j.bbrc.2007.06.068 CrossRefPubMed

Mäkelä J, Tselykh TV, Maiorana F, Eriksson O, Do HT, Mudò G, Korhonen LT, Belluardo N, Lindholm D (2014) Fibroblast growth factor-21 enhances mitochondrial functions and increases the activity of PGC-1α in human dopaminergic neurons via Sirtuin-1. SpringerPlus 3:1–12CrossRef

Martyn JA, Kaneki M, Yasuhara S (2008) Obesity-induced insulin resistance and hyperglycemia: etiologic factors and molecular mechanisms. Anesthesiology 109:137–148. doi:10.1097/ALN.0b013e3181799d45 CrossRefPubMed

Meshkani R, Adeli K (2009) Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 42:1331–1346. doi:10.1016/j.clinbiochem.2009.05.018 CrossRefPubMed

Mlinar B, Marc J, Janez A, Pfeifer M (2007) Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta 375:20–35. doi:10.1016/j.cca.2006.07.005 CrossRefPubMed

Moyers JS et al (2007) Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J Cell Physiol 210:1–6. doi:10.1002/jcp.20847 CrossRefPubMed

Nishimura T, Nakatake Y, Konishi M, Itoh N (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492:203–206CrossRefPubMed

Ogawa Y et al (2007) BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A 104:7432–7437. doi:10.1073/pnas.0701600104 CrossRefPubMedPubMedCentral

Owen BM et al (2013) FGF21 contributes to neuroendocrine control of female reproduction. Nat Med 19:1153–1156. doi:10.1038/nm.3250 CrossRefPubMedPubMedCentral

Owen BM et al (2014) FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab 20:670–677. doi:10.1016/j.cmet.2014.07.012 CrossRefPubMedPubMedCentral

Pelz KM, Dark J (2007) ICV NPY Y1 receptor agonist but not Y5 agonist induces torpor-like hypothermia in cold-acclimated Siberian hamsters. Am J Physiol Regul Integr Comp Physiol 292:R2299–R2311. doi:10.1152/ajpregu.00790.2006 CrossRefPubMed

Potthoff MJ et al (2009) FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A 106:10853–10858. doi:10.1073/pnas.0904187106 CrossRefPubMedPubMedCentral

Sarruf DA, Thaler JP, Morton GJ, German J, Fischer JD, Ogimoto K, Schwartz MW (2010) Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 59:1817–1824. doi:10.2337/db09-1878 CrossRefPubMedPubMedCentral

Shoelson SE, Herrero L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132:2169–2180. doi:10.1053/j.gastro.2007.03.059 CrossRefPubMed

So WY, Cheng Q, Xu A, Lam KS, Leung PS (2015) Loss of fibroblast growth factor 21 action induces insulin resistance, pancreatic islet hyperplasia and dysfunction in mice. Cell Death Dis 6, e1707. doi:10.1038/cddis.2015.80 CrossRefPubMedPubMedCentral

Tan BK, Hallschmid M, Adya R, Kern W, Lehnert H, Randeva HS (2011) Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: relationship with plasma FGF21 and body adiposity. Diabetes 60:2758–2762. doi:10.2337/db11-0672 CrossRefPubMedPubMedCentral

Tomiyama K et al (2010) Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc Natl Acad Sci U S A 107:1666–1671. doi:10.1073/pnas.0913986107 CrossRefPubMedPubMedCentral

Uebanso T et al (2011) Paradoxical regulation of human FGF21 by both fasting and feeding signals: is FGF21 a nutritional adaptation factor? PLoS One 6, e22976. doi:10.1371/journal.pone.0022976 CrossRefPubMedPubMedCentral

Umegaki H (2010) Pathophysiology of cognitive dysfunction in older people with type 2 diabetes: vascular changes or neurodegeneration? Age Ageing 39:8–10. doi:10.1093/ageing/afp211 CrossRefPubMed

Wente W et al (2006) Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55:2470–2478. doi:10.2337/db05-1435 CrossRefPubMed

Wu Z et al (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98:115–124. doi:10.1016/S0092-8674(00)80611-X CrossRefPubMed

Yang C, Jin C, Li X, Wang F, McKeehan WL, Luo Y (2012a) Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One 7, e33870. doi:10.1371/journal.pone.0033870 CrossRefPubMedPubMedCentral

Yang M, Zhang L, Wang C, Liu H, Boden G, Yang G, Li L (2012b) Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance. PLoS One 7, e48392. doi:10.1371/journal.pone.0048392 CrossRefPubMedPubMedCentral

Yu H et al (2011) Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin Chem 57:691–700. doi:10.1373/clinchem.2010.155184 CrossRefPubMed

Yu Y et al (2015) Fibroblast growth factor 21 protects mouse brain against d-galactose induced aging via suppression of oxidative stress response and advanced glycation end products formation. Pharmacol Biochem Behav. doi:10.1016/j.pbb.2015.03.020

Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM (2006) Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 281:15694–15700. doi:10.1074/jbc.M601252200 CrossRefPubMedPubMedCentral

Zhang Y et al (2012) The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. eLife 1, e00065. doi:10.7554/eLife.00065 CrossRefPubMedPubMedCentral

Titel: Potential roles of fibroblast growth factor 21 in the brain
verfasst von: Piangkwan Sa-nguanmoo
Nipon Chattipakorn
Siriporn C. Chattipakorn
Publikationsdatum: 01.04.2016
Verlag: Springer US
Erschienen in: Metabolic Brain Disease / Ausgabe 2/2016
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-015-9789-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Behavioral effects of citrus paradisi in rats

Diabetes enhances oxidative stress-induced TRPM2 channel activity and its control by N-acetylcysteine in rat dorsal root ganglion and brain

Puerarin ameliorates cognitive deficits in streptozotocin-induced diabetic rats

Accumulation of reactivity to MBP sensitizes TRAIL mediated oligodendrocyte apoptosis in adult sub cortical white matter in a model for human multiple sclerosis

Reduced cerebral cortical thickness in Non-cirrhotic patients with hepatitis C